ReviewCardiovascular therapeutics2014

The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.

Marc Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.